Artificial intelligence–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response-Reference-Cited by-同舟云学术

Artificial intelligence–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response

Published:2022-07 Issue: Volume:170 Page:17-26
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Choi Sangjoon,Cho Soo Ick^ORCID,Ma Minuk,Park Seonwook,Pereira Sergio,Aum Brian Jaehong^ORCID,Shin Seunghwan^ORCID,Paeng Kyunghyun,Yoo Donggeun,Jung Wonkyung,Ock Chan-Young,Lee Se-Hoon,Choi Yoon-La,Chung Jin-Haeng,Mok Tony S.,Kim Hyojin,Kim Seokhwi^ORCID

Funder

Seoul National University Bundang Hospital

Lunit

National Research Foundation of Korea

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference39 articles.

1. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS;Park;Ann Oncol,2020

2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

3. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057);Horn;J Clin Oncol,2017